ABP 130
Alternative Names: ABP-130Latest Information Update: 28 Aug 2024
At a glance
- Originator Abpro Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 24 Jul 2020 Preclinical trials in Colorectal cancer in USA (Parenteral) (Abpro Therapeutics pipeline, July 2020)